Su Jing-shi, Arima Kiminobu, Hasegawa Mariko, Franco Omar E, Umeda Yoshiki, Yanagawa Makoto, Sugimura Yoshiki, Kawamura Juichi
Department of Urology, Faculty of Medicine, Mie University, Tsu, Mie, Japan.
Int J Urol. 2004 Feb;11(2):74-82. doi: 10.1111/j.1442-2042.2004.00752.x.
To examine the expression of the KAI1 metastasis suppressor gene and to evaluate its relationship with tumor recurrence in primary pTa and pT1 urothelial bladder carcinoma.
Samples were obtained from 87 patients after transurethral resection (TUR). Tumor stage and grade were reviewed in 33 patients with pTa and in 54 patients with pT1, with a mean follow-up time of 47.4 +/- 30.1 months. The KAI1 protein immunohistochemical assay was performed. Prognosis was analyzed using the Kaplan-Meier method and Cox's proportional hazards model. Correlation between KAI1 expression and recurrence according to each clinicopathological factor was comparatively evaluated using the chi-squared test.
Decreased expression of KAI1 protein failed to reach statistical significance for stage (P = 0.25) or morphology of tumor stem (P = 0.19), but it was significantly related to tumor size (P = 0.016). The recurrence-free 5-year survival rates of the group with decreased KAI1 expression was 69.7%, which was significantly higher than the 22.2% for the KAI1-positive group (P < 0.0001). In univariate and multivariate analyses, decreased expression of KAI1 protein, stage pT1, tumor size >3 cm and sessile tumors were independent prognosis factors of recurrence. Despite the lower recurrence rate expected by considering only the clinicopathological factors, decreased KAI1 expression was able to identify the group with a high risk of recurrence.
Downregulated KAI1 expression in bladder tumors tends to relate to stage and morphology of the tumor stem and was significantly correlated to tumor size. Decreased expression of KAI1 was associated with the degree of invasiveness and progression of the cancer and was an independent prognostic factor of recurrence in primary pTa and pT1 urothelial bladder carcinoma.
检测KAI1转移抑制基因的表达,并评估其与原发性pTa和pT1期膀胱尿路上皮癌肿瘤复发的关系。
经尿道切除术(TUR)后从87例患者获取样本。对33例pTa期和54例pT1期患者的肿瘤分期和分级进行复查,平均随访时间为47.4±30.1个月。进行KAI1蛋白免疫组织化学检测。采用Kaplan-Meier法和Cox比例风险模型分析预后。使用卡方检验比较评估KAI1表达与根据各临床病理因素的复发之间的相关性。
KAI1蛋白表达降低在肿瘤分期(P = 0.25)或肿瘤主干形态(P = 0.19)方面未达到统计学意义,但与肿瘤大小显著相关(P = 0.016)。KAI1表达降低组的5年无复发生存率为69.7%,显著高于KAI1阳性组的22.2%(P < 0.0001)。在单因素和多因素分析中,KAI1蛋白表达降低、pT1期、肿瘤大小>3 cm和无蒂肿瘤是复发的独立预后因素。尽管仅考虑临床病理因素预期复发率较低,但KAI1表达降低能够识别出复发风险高的组。
膀胱肿瘤中KAI1表达下调往往与肿瘤主干的分期和形态有关,且与肿瘤大小显著相关。KAI1表达降低与癌症的侵袭程度和进展相关,是原发性pTa和pT1期膀胱尿路上皮癌复发的独立预后因素。